Webinar via Zoom. Webinar link to the event will be sent to you after registering.
Eliminating hepatitis C in prisons will be a crucial setting if World Health Organization (WHO) elimination targets are to be achieved. For World Hepatitis Day, we’ll hear from experts about the evidence that treatment as prevention in prisons works, and how it can be rolled out in Australia to have the most effective impact. Drawing on findings from the Surveillance and treatment of prisoners with hepatitis C (SToP-C) study, the panel will also discuss the importance of integration with drug dependence management.
The webinar is presented through the ASCEND program grant (Advancing the health or people who use drugs: hepatitis C and drug dependence), a collaboration between UNSW Sydney’s Kirby Institute and National Drug and Alcohol Research Centre (NDARC), funded by the National Health and Medical Research Centre.
- Professor Gregory Dore, Program Head, Kirby Institute
- Dr Behzad Hajarizadeh, Senior Lecturer, Kirby Institute
Hepatitis C treatment-as-prevention in the prison setting: The SToP-C Study
- Dr Lise Lafferty, Research Fellow, Kirby Institute
Perceptions and concerns of hepatitis C reinfection within the prison setting
- Professor Andrew Lloyd, Program Head, Kirby Institute
A guide to scale-up of testing and treatment in prisons: the SToP-C Implementation Toolkit
- Professor Adrian Dunlop, Director, Drug and Alcohol Clinical Services, Hunter New England Local Health District
Understanding NSW long-acting opioids in custody: the UNLOC-T study
Followed by a panel discussion and Q&A session.
Professor Gregory Dore
Gregory Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 20 years. He has developed extensive national and international collaborations, and is internationally recognized in the areas of HCV natural history and epidemiology, therapeutic strategies for acute and chronic HCV infection, particularly among people who inject drugs, and HCV elimination strategies.
Dr Behzad Hajarizadeh
Behzad Hajarizadeh is a Senior Lecturer in the Viral Hepatitis Clinical Research Program (VHCRP), the Kirby Institute. He trained as a Medical Practitioner and has a Masters in Public Health (MPH) and PhD in Medicine (Clinical Epidemiology). His main area of expertise is viral hepatitis with more than 15 years experience as a clinician and researcher in the field of liver diseases. His employment history includes working as a Research Fellow in La Trobe University, Melbourne and as a Senior Research Officer and Project Coordinator in the Ministry of Health and UNAIDS country office in Iran.
Dr Lise Lafferty
Lise Lafferty is a Research Fellow with a co-appointment across the Centre for Social Research in Health and the Surveillance Evaluation and Research Program, The Kirby Institute. Her research interests include people who inject drugs (including those in prison and in the community), blood-borne viruses (particularly hepatitis C), sexual health, and Aboriginal health. She has a community background working with diverse disadvantaged communities including people with disabilities, young people at risk of entering the criminal justice system, and Aboriginal communities.
Professor Andrew Lloyd
Andrew Lloyd is an infectious diseases physician, and an epidemiology, virology and immunology researcher. He is an NHMRC Practitioner Fellow. He is the Head of the Viral Immunology Systems Program (VISP) in the Kirby Institute, and Director of the UNSW Fatigue Clinic and Research Program at the University of NSW. He also provides clinical services in infectious diseases at Prince of Wales Hospital, and hepatology services to Justice Health in the NSW prisons. His research program has been continuously funded by NHMRC since 1993.